Previous close | 48.93 |
Open | 49.00 |
Bid | 49.05 x 900 |
Ask | 49.53 x 800 |
Day's range | 48.87 - 49.56 |
52-week range | 47.58 - 70.94 |
Volume | |
Avg. volume | 15,525,840 |
Market cap | 99.595B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 12.73 |
EPS (TTM) | 3.86 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 2.40 (4.88%) |
Ex-dividend date | 04 Apr 2024 |
1y target est | 56.00 |
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif., April 22, 2024--Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies....